Search in:

Advanced search

International Journal of Women's Health Volume 4, 2012 - Issue

Submit an article Journal homepage

Open access

127

Views

CrossRef citations to date

Altmetric

Original Research

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery

Josep L Carbonell Esteve1 Mediterránea Médica Clinic, Valencia, SpainCorrespondence[email protected] [email protected]

Ana M Riverón2 Eusebio Hernández Obstetrics Teaching Hospital, Havana, Cuba

Mariela Cano2 Eusebio Hernández Obstetrics Teaching Hospital, Havana, Cuba

Alma I Ortiz3 Alemán Hospital, Managua, Nicaragua

Aleta Valle2 Eusebio Hernández Obstetrics Teaching Hospital, Havana, Cuba

Carlos S Texidó2 Eusebio Hernández Obstetrics Teaching Hospital, Havana, Cuba

Giuseppe Tomasi4 Chemistry Department, University of the Basque Country, San Sebastian, Spain

show all

Pages 75-84 | Published online: 13 Mar 2012

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

DayBDDunsonDBHillMCCoousinsDSchectmanJMHigh cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidenceAm J Obstet Gynecol2003188110010712548202
PubMed Web of Science ®Google Scholar
WegienkaGBairdDDHertz-PicciotoISelf-reported heavy bleeding associated with uterine leiomyomataObstet Gynecol2003101343143712636944
PubMed Web of Science ®Google Scholar
WilcoxLSKooninLMPokrasRStraussLTXiaZPetersonHBHysterectomy in the United States, 1988–1990Obstet Gynecol19948345495558134065
PubMed Web of Science ®Google Scholar
WilsonEAYangFReeseEEstradiol and progesterone binding in uterine leiomyomata and in normal uterine tissuesObstet Gynecol198055120247352057
PubMed Web of Science ®Google Scholar
AndersenJFactors in fibroid growthBaillieres Clin Obstet Gynaecol199812222524310023420
PubMed Web of Science ®Google Scholar
ReimMSBarbierRLFriedmanAJProgesterone: a critical role in the pathogenesis of uterine myomaAm J Obstet Gynecol19951721 Pt 114187847524
PubMed Web of Science ®Google Scholar
SteinauerJPrittsEAJacksonRJacobyASystematic review of mifepristone for the treatment of uterine leiomyomataObstet Gynecol200410361331133615172874
PubMed Web of Science ®Google Scholar
EngmanMGranberSWilliamsARMengCXLalitkumarPGGemzell-DanielssonKMifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trialHum Reprod20092481870187919389793
PubMed Web of Science ®Google Scholar
EisingerSHMeldrumSFiscellaKle RouxHDGuzickDSLow-dose mifepristone for uterine leiomyomataObstet Gynecol2003101224325012576246
PubMed Web of Science ®Google Scholar
Alvarez-MurphyAAKettelLMMoralesAJRobertsVJYenSSRegression of uterine leiomyomata in response to the antiprogesterone RU 486J Clin Endocrinol Metabol1993762513517
Web of Science ®Google Scholar
ReinschRCMurphyAAMoralesAJYenSSThe effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized studyAm J Obstet Gynecol19941706162316288203418
PubMed Web of Science ®Google Scholar
YangYZhengSLiKTreatment of uterine leiomyomata by two different doses of mifepristoneZhonghua Fu Chan Ke Za Zhi19963110624626 Chinese9275461
PubMedGoogle Scholar
ZengCGuMHuangHA clinical control study on the treatment of uterine leiomyomata with gonadotropin releasing hormone agonist or mifepristoneZhonghua Fu Chan Ke Za Zhi1998338490492 Chinese10806751
PubMedGoogle Scholar
EisingerSHBonfiglioTFiscellaKMeldrumSGuzickDTwelve-month safety and efficacy of low-dose mifepristone for uterine myomasJ Min Invasiv Gynecol2005123227233
Web of Science ®Google Scholar
BagariaMSunejaAVaidNBGuleriaKMishraKLow-dose mifepristone in treatment of uterine leiomyoma: a randomized double-blind placebo-controlled trialAust NZJ Obstet Gynecol20094917783
Web of Science ®Google Scholar
CarbonellJLAcostaRHerediaBPérezYYeroMCValleAMifepristone for the treatment of uterine leiomyomas: a randomized controlled trialObstet Gynecol200811251029103618978102
PubMed Web of Science ®Google Scholar
CarbonellJLQuiróz RámirezGMBorgeACastellón ZapataLECuadra AragónWGiuseppe TomasiGMifepristone 5 mg versus 10 mg daily for treatment of leiomyomaProg Obstet Gynecol20091018
Google Scholar
CarbonellJLAcostaRHerediaBEvolution of uterine leiomyoma after treatment with mifepristone: a randomized clinical trialProg Obstet Ginecol2010536231236
Google Scholar
CarbonellJLAcostaRHerediaBMifepristone for treatment of uterine fibroidsRev Cub Gynecol Salud Reprod2010362236250
Google Scholar
FiscellaKEisingerSHMeldrumSEffect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trialObstet Gynecol200610861381138717138770
PubMed Web of Science ®Google Scholar
EisingerSHFiscellaJBonfiglioTMeldrumSFiscellaKOpen-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomataEur J Obstet Gynecol20091462215218
Web of Science ®Google Scholar
BairdDTBrownACritchleyHOWilliamsARLinSChengLEffect of long-term treatment with low-dose mifepristone on the endometriumHum Reprod2003181616812525442
PubMed Web of Science ®Google Scholar
Guidance for IndustryDrug-Induced Liver Injury: Premarketing Clinical EvaluationUS Department of Health and Human Services72009 Available from: http://www.ccd.org.cn/ccd/fs/web_edit_file/20090807144518.pdfAccessed February 13, 2012
Google Scholar
MutterGLBergeronCDeligdischLThe spectrum of endometrial pathology induced by progesterone receptor modulatorsMod Pathol200821559159818246050
PubMed Web of Science ®Google Scholar
HorneFMBlitheDLProgesterone receptor modulators and the endometrium: changes and consequencesHum Reprod Update200713656758017630398
PubMed Web of Science ®Google Scholar
FaulFG*Power version 3.0.10Kiel, GermanyUniversitat Kiel2008
Google Scholar
FiscellaFBonfiglioTWintersPEisingerSHFiscellaKDistinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristoneHum Pathol201142794795321315422
PubMed Web of Science ®Google Scholar
IoffeOBZainoRJMutterGLEndometrial changes from short-term therapy with CDB-4121, a selective progesterone receptor modulatorMod Pathol200922345045919136935
PubMed Web of Science ®Google Scholar
LevensEDPotlog-NahariCArmstrongACDB-2914 for uterine leiomyomata treatment: a randomized controlled trialObstet Gynecol200811151129113618448745
PubMed Web of Science ®Google Scholar
NiemanLKBlockerWNanselTEfficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb studyFertil Steril201195276777221055739
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date